Alfons Grunenberg
Bayer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alfons Grunenberg.
International Journal of Pharmaceutics | 1995
Alfons Grunenberg; B. Keil; J.-O. Henck
Abstract The results of studies on nimodipine in the solid state demonstrate that the compound occurs in two polymorphic forms. Modification I melts at + 124°C and crystallizes as the racemic compound. Modification II (m.p. + 116°C) is a conglomerate. The two polymorphs have been characterized by means of differential scanning calorimetry, infrared, Raman, and 13C-NMR spectroscopy, X-ray powder diffractometry, X-ray structure analysis, pycnometry, and solubility measurements. The thermodynamic relationships are illustrated in a semi-schematic energy/temperature diagram, which gives information about the relative stability and physical properties of the two modifications. Modification II is the stable form between absolute zero and about + 90°C. The melting characteristics of the two polymorphs are illustrated by the phase diagram. Modification I is yellow. Modification II is almost white. The differences in colour are discussed with reference to the results of X-ray structure analyses and the UV-Vis spectra.
Archive | 1996
Alfons Grunenberg; Patrick Bosche
Archive | 2003
Peter Serno; Alfons Grunenberg; Andreas Ohm; Rainer Bellinghausen; Eimer Vollers; Jan-Olav Henck
Pharmazie in Unserer Zeit | 1997
Alfons Grunenberg
Archive | 1996
Alfons Grunenberg; Oliver Dr Brehm; Michael Conrad; Dietrich Seidel
Archive | 2005
Alfons Grunenberg; Jana Lenz
Archive | 2007
Alfons Grunenberg; Juergen Stiehl; Katharina Tenbieg; Birgit Keil
Archive | 2007
Alfons Grunenberg; Juergen Stiehl; Katharina Tenbieg; Birgit Keil
Archive | 1996
Alfons Grunenberg; Patrick Bosche
Archive | 2014
Birgit Keil; Franz-Josef Mais; Winfried Joentgen; Alfons Grunenberg